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HERPES ZOSTER
TREATMENT OF PAIN WITH DEHYDROERGOTAMINE45*
FRANK C. COMBES, M.D., ORLANDO CANIZARES, M.D., AND SOCORRO
SIMUANGCO, M.D.
MØller (1) of Copenhagen was first to use a derivative of ergot in the treatment of the
neuralgia of herpes zoster. He obtained satisfactory results in six patients by giving 0.5 cc.
of gynergen daily for 3 days and 1 cc. daily for the following three days. Stokly (2) treated
6 patients following the schedule recommended by MØller with satisfactory results. He
found that 0.25 cc. of gynergen for 6 consecutive days proved satisfactory. He states further
that information received from Scandinavian physicians showed that in severe cases of
herpes zoster the dose may be increased to 1 cc. (0.5 mg.) during the first day of treatment
and that this dose may be continued for more than 6 days if necessary. Hensler (3) also ob
tamed complete disappearance of pain in 14 patients in whom the drug was given the first
three days of the eruption.
The clinical efficacy of dehydroergotamine methanesulfonate (DHE 45) in the treatment
of migraine headaches is already well known; having been reported by Horton and others
(4). Information regarding its pharmacologic action has been presented by Rothlin (5).
Orth and Ritchie (6) showed that DHE 45 must be administered in at least twice as great
an amount as ergotamine tartrate ("gynergen") for comparable therapeutic results.
In this study we present our experience in the treatment of herpes zoster
with DHE 45.
MATERIAL
Forty patients with herpes zoster were treated with dehydroergotamine. Of
these 17 were women and 23 were men. Their ages varied from 16 to 75 years.
The duration of the lesions was from 2 days to a post-herpetic pain of 6 months'
duration; the average duration was 1 to 3 weeks. The location of the eruption
varied. No sedation was given. Local treatment usually was confined to calamine
lotion. Placebos, in the form of injections of distilled water, were often given for
control purposes.
The medication was administered by intramuscular or intravenous injection.
Most of the doses given were of 1 cc. although in some instances 2 or even 3 cc.
were given in one injection. The number of injections was from 1 to 13 cc., the
average being 4 to 6 cc. The interval between doses was often 24 hours but it
varied considerably depending on the length of the relief obtained. Since treat-
ments were given only when needed for the relief of pain, the intervals fluctuated
between 12 hours and 4 days. Most of the injections were given intramuscularly,
although the intravenous route was sometimes used for comparative purposes.
No difference in effect was noted.
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RESULTS
The results obtained were divided into three categories:
(A) Excellent
A total of 17 cases were included in this group. They are summarized in Table I.
The criteria for inclusion in this group was complete relief from pain following
each injection. In seven cases the drug was administered intravenously and in 10
intramuscularly. In most instances the pain disappeared in fifteen to twenty
minutes. In other instances the pain decreased considerably but was still present.
TABLE I
"Excellent"
NUMBER
INITIALS AGE SEX LOCATION DURATION I;S TOTAL
cc.
1 F. S. 61 F R. Ophth. 4 days 6 I.V. 6
2 0. M. 70 F R. Abd. 8 days 5 I.M. 5
3 M.R. 46 F R.Arm iweek 2 I.M. 2
4 J. M. 34 M R. Chest 2 weeks 2 I.V. 2
5 E. D. 25 M Chest 4 days 1 I.V. 1
6 J. M. 37 F L. Neck 5 days 3 I.V. 8
7 C.L. 24 M L.Arm iweek 2 I.V. 2
8 J. F. 56 M L. Chest 1 week 3 I.V. 6
9 A. W. 34 F L. Chest 3 weeks 3 I.V. 4
10 A. S. 59 M L. Lumbar 3 days 3 I.M. 5
11 A. F. 74 M H. Abd. 5 days 3 I.M. 5
12 H. D. 48 M R. Ophth. 1 week 4 I.M. 6
13 C. W. 35 M L. Arm 3 days 1 I.M. 2
14 M. T. 62 F L. Neck 6 days 2 I.M. 4
15 R. S. 62 F L. Arm 2 days 3 I.M. 6
16 P. F. 39 M Neck 5 days 3 I.M. 3
17 M. R. 30 F Abd. 6 days 4 I.M. 6
In two cases but one injection was needed to obtain complete and permanent
relief. Often patients stated that following the first injection they had a night
without pain, allowing them to sleep well for the first time since the onset of the
neuralgia. The period of relief obtained varied between 8 hours and 3 days. Most
patients received three to four injections; one required five and another, six.
The clinical course of the eruption was not appreciably affected by the medica-
tion. The pain disappeared irrespective of the stage of the eruption which con-
tinued its clinical course unaffected.
(B) Satisfactory
Thirteen cases were included in this group (Table II). In this group, although
the over-all results were satisfactory, some of the injections failed to effect relief
of the pain or the relief obtained was mild. Often when one injection failed it was
followed by another of a higher dose which usually produced satisfactory results.
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From one to seven injections were given. The total dosage required varied from
1 to 13 cc.; the average was 6 cc.
TABLE II
"Satisfactory"
15GM-
NUMBER
BEE INITIALS AGE SEX LOCATION DTRATION OP IN- TOTAL
cc.
1 E.B. 62 M R.Arm 3 weeks 4 I.V. 5
2 J. C. 52 M II. Leg 1 week 4 TM. 4
3 N. A. 42 F R. Ophth. 3 weeks 5 I.M. 5
4 R. Z. 22 M L. Abd. 1 week 2 I.M. 2
5 G. P. 37 F R. Chest 4 days 4 I.M. 4
6 J. E. 42 M L. Chest 10 days 3 I.M. 3
7 L. V. 16 F L. Chest 1 week 1 I.V. 1
8 C. B. 55 F L. Abd. 3 days 4 I.V. 8
9 S. P. 63 F R. Mandib. 5 days 7 TM. 11
10 P. S. 74 M It. Ophthal. 1 week 4 I.M. 7
11 P. T. 64 F L. Neck 1 week 6 I.M. 13
12 S. L. 68 M L. Face 4 days 4 I.M. 9
13 It. R. 30 F L. Abd. 6 days 4 I.M. 6
TABLE III
"Failure"
NUMBER
INITIALS AGE SEX LOCATION DURATION TOTAL
cc.
1 A. M. 75 M R. Ophthal. 3 days 3 I.M. 3
2 B. W. 55 M Post-herpetic 6 weeks 4 I.M. 4
pain
3 L. L. 40 M R. Ophthal. 7 weeks 5 I.M. 5
Post-herpetic
pain
4 A. K. 46 M L. Chest 1 week 6 I.M. 6
5 T. E. 38 M R. Mandib. 3 days 8 I.M. 8
6 V. G. 19 M L. Thigh 1 week 8 I.V. 13
7 F. K. 66 M It. Neck 1 week 2 I.M. ii
8 J. II. 52 M It. Arm 1 week 2 I.M. 4
9 M. L. 71 F Post-herpetic 6 months 6 I.M. 6
pain
10 M. R. 75 F Chest, post-her- 4 weeks 1 I.M. 6
petic pain
(C) Failures
The ten cases which were considered failures are summarized in Table III.
The criterion for inclusion in this group was failure to obtain satisfactory relief
from pain in most of the injections. In some patients, some of the injections led
to moderate, temporary relief.
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In this group there were several rather unusual cases. One patient had leu-
kemia, another had carcinoma of the lung with metastases. Four cases of post-
herpetic pain, mostly in elderly patients were also included in this group. The
neuralgia in those cases was of long duration, the longest having been present for
six months.
COMPLICATIONS
Side effects were minimal. In two patients there was temporary moderate
fall of blood pressure; a decrease of 10 to 15 mm. systolic pressure occurring
shortly after the injection but returning to normal within an hour. Temporary
bradycardia was noted on two occasions. A moderate headache lasting for a few
hours was reported by one patient and another had nausea and vomited after
each injection.
COMMENT AND SUMMARY
A study of results obtained in the treatment of 40 cases of herpes zoster with
pain shows that Dehydroergotamine 45 controlled the pain in 30 of 40 patients
(75 per cent). In 17 instances the results were classified as "excellent" and in 13
as "satisfactory."
There were 10 "failures." These included one patient with leukemia, one with
primary pulmonary carcinoma with metastases and 4 with post-herpetic pain
of protracted duration.
The location and duration of the eruption did not influence response to therapy
except in instances of long standing post-herpetic pain. The clinical course of the
eruption was not affected by the medication. In those instances where treatment
was started early, new crops of vesicles often appeared after the first injection.
In most patients these vesicles dried in an average of one to two weeks.
There was no appreciable advantage in intravenous administration except that
results were more prompt. In most cases the intramuscular route was satisfactory.
The dose of 1 cc. was found to give good results, but when it failed a larger dose
(2—3 cc.) was often successful.
The duration of relief from pain varied from 8 hours to 4 days. There were no
serious side-effects.
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